Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer SAN CARLOS,…

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

More from Monday 19 October →